-
Sodium chloride versus glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED-AHF): A prospective, randomized, mechanistic study Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-02
Jan Biegus, Gracjan Iwanek, Jeffrey Testani, Robert Zymliński, Marat Fudim, Mateusz Guzik, Piotr Gajewski, Piotr Ponikowski -
Profiling hypotension in heart failure based on office, orthostatic and ambulatory blood pressure measurements Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-06-02
Anzhela Soloveva, Darya Fedorova, Sabina Kuchinskaia, Amina Rakisheva, Victoria Galenko, Andrey Kozlenok, Svetlana VillevaldeClick on the article title to read more.
-
Ferroptosis in cardiovascular disease: regulatory mechanisms and therapeutic implications Eur. Heart J. (IF 37.6) Pub Date : 2025-06-04
Yiheng Zhao, Andreas Linkermann, Masafumi Takahashi, Qingguo Li, Xiang ZhouFerroptosis, an iron-dependent form of regulated cell death, has been identified as a key factor in the pathogenesis and progression of various cardiovascular diseases (CVDs). The molecular basis of ferroptosis involves lipid peroxidation, iron dysregulation, and antioxidant pathways. Accumulating evidence suggests that ferroptosis is associated with various CVDs, including atherosclerosis, myocardial
-
Think Aorta: aortic dissection awareness and perspectives from the patient Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2025-06-03
Gareth Owens -
Heat extremes and cardiovascular diseases: a scientific statement of the Association of Cardiovascular Nursing & Allied Professions, Association for Acute Cardiovascular Care, European Association of Preventive Cardiology, Heart Failure Association, European Heart Rhythm Association of the ESC, the ESC Council on Hypertension, the ESC Council on Stroke, and the ESC Working Group on Cardiovascular Pharmacotherapy Eur. Heart J. (IF 37.6) Pub Date : 2025-06-03
Georgia K Chaseling, Izabella Uchmanowicz, Maria Bäck, Òscar Miró, Maryia Tokmakova, Petter Ljungman, Jari Laukkanen, Rosa Maria Bruno, George Ntaios, Bianca Rocca, Ollie Jay, Lacy M Alexander, W Larry Kenney, Philip MoonsGlobally, hot weather and heatwaves are claiming lives and are predicted to become increasingly deadly under all future climate change scenarios. Rising global temperatures pose a significant risk on cardiovascular health, disproportionately impacting the elderly and people with cardiovascular disease (CVD). However, despite convincing epidemiological data demonstrating this increased cardiovascular
-
Obesity and heart failure: exploring the cardiometabolic axis Cardiovasc. Res. (IF 10.2) Pub Date : 2025-06-03
Jennifer J Rayner, Ines Abdesselam, Jiliu Pan, Andrew J M Lewis, Oliver J RiderObesity is one of the biggest risks to public health in both developed and developing countries, and yet incidence continues to skyrocket. Being the main risk factor for a large number of life-limiting conditions, obesity has the potential to cause enormous damage unless addressed urgently. Heart failure (HF) is the most common cardiovascular disease associated with obesity. The incidence of HF overall
-
A rare gain of function variant of hepatic lipase attenuates hypercholesterolemia and atherosclerosis in mice via an LDL receptor-independent mechanism Cardiovasc. Res. (IF 10.2) Pub Date : 2025-06-03
Thibaud Sotin, Xiaoke Ge, Milena Schönke, Lucie Vince, Amélie Thouzeau, Samuel Frey, Victoria Lorant, Lisa Krul, Amanda C M Pronk, Reshma Lalai, Trea C M Streefland, Salwa Afkir, Wieneke Dijk, Sarra Smati, Marieke Heijink, Niek Blomberg, Martin Giera, Mathilde Di Filippo, Philippe Moulin, Sander Kooijman, Bertrand Cariou, Patrick C N Rensen, Cédric Le MayAims LIPC encodes hepatic lipase (HL), a liver-bound protein with both phospholipase and triglyceride lipase activity, and involved in the catabolism of circulating lipoproteins. We recently identified the gain-of-function variant HL-E97G, with selectively increased phospholipase activity, as a new genetic cause of familial combined hypocholesterolemia in humans. The role of HL in the development of
-
Platelets and inflammation - insights from platelet non-coding RNA content and release in the Bruneck Study and the PACMAN-AMI trial Cardiovasc. Res. (IF 10.2) Pub Date : 2025-06-03
Clemens Gutmann, Temo Barwari, Christian Schulte, Konstantinos Theofilatos, Bhawana Singh, Kaloyan Takov, Gonca Suna, Melissa V Chan, Paul C Armstrong, Christian Cassel, Yasushi Ueki, Jonas D Häner, Peter Santer, Peter Willeit, Christian Hengstenberg, Lorenz Räber, Stefan Kiechl, Johann Willeit, Timothy D Warner, Manuel MayrAims Platelets contain non-coding RNAs (ncRNAs), and their measurement may complement platelet aggregometry. Methods and results In the community-based Bruneck Study (n = 338), we generated platelet-rich plasma (PRP), platelet-poor plasma (PPP) and platelets. PRP was subjected to aggregometry using various agonists and processed to platelet releasates thereafter. Releasates, PPP and platelets underwent
-
Single-cell epigenomic and transcriptomic analysis unveils the pivotal role of GATA5/ISL1+ fibroblasts in cardiac repair post-myocardial infarction Cardiovasc. Res. (IF 10.2) Pub Date : 2025-06-03
Shuchen Zhang, Boyang Xiang, Yiheng Zhao, Wenjing Wang, Lili Chen, Xiang ZhouAims A comprehensive understanding of the genome-wide regulatory landscape of the cardiac tissues post-myocardial infarction (MI) is still lacking. We therefore integrated single-cell RNA sequencing (scRNA-seq) and single-cell for transposase-accessible chromatin sequencing (scATAC-seq) to elucidate the epigenetic landscape of the heart post-MI. Methods and results We established MI mice through ligation
-
Ceramides in cardiovascular disease – emerging role as independent risk predictors and novel therapeutic targets Cardiovasc. Res. (IF 10.2) Pub Date : 2025-06-03
Roland Klingenberg, Andreas Leiherer, Dobromir Dobrev, Juan C Kaski, Bodo Levkau, Winfried März, Samuel Sossalla, Arnold von Eckardstein, Heinz DrexelCeramides are bioactive lipid mediators involved in apoptosis, inflammation, and fibrosis. This narrative review provides a concise overview of the emerging role of ceramides in cardiovascular disease with emphasis on atherosclerotic vascular disease and heart failure, suggesting a potential use of ceramides in risk stratification and as putative therapeutic targets. Recent developments based on observational
-
-
Contents J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Section snippets A New Chapter for Guidelines in JACC2055Harlan M. Krumholz Acute Coronary Syndromes: A Holistic View2057Elliott M. Antman, Eugene Braunwald The Long-Awaited American ACS Guideline: Closer to a Universal Document2061Valentin Fuster, Borja Ibanez A Quarter Century of ACS Guidelines: Gaps Within Evidence Gaps2064Celina M. Yong, Robert M. Califf The 2025 American College of Cardiology/American
-
A New Chapter for Guidelines in JACC J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Harlan M. KrumholzSection snippets Funding Support and Author DisclosuresIn the past 3 years, Dr Krumholz has received options for Element Science and Identifeye and payments from F-Prime for advisory roles; was a co-founder of and held equity in Hugo Health; is a co-founder of and holds equity in Refactor Health and ENSIGHT-AI; and is associated with research contracts through Yale University from Janssen, Kenvue,
-
Acute Coronary Syndromes: A Holistic View J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Elliott M. Antman, Eugene BraunwaldSection snippets Historical PerspectiveCoronary atherosclerosis, long believed to be a recently developed disorder, was identified in Egyptian mummies who lived >4,000 years ago.1 In 1879, Ludvig Hektoen, an American pathologist, proposed that coronary artery thrombosis was the basis of acute myocardial infarction (MI).2 In 1910, 2 Ukrainian physicians, Obraztsov and Strazhesko, described 3 patients
-
The Long-Awaited American ACS Guideline: Closer to a Universal Document J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Valentin Fuster, Borja IbanezSection snippets Funding Support and Author DisclosuresThe authors have reported that they have no relationships relevant to the contents of this paper to disclose.
-
A Quarter Century of ACS Guidelines: Gaps Within Evidence Gaps J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Celina M. Yong, Robert M. CaliffSection snippets Funding Support and Author DisclosuresThe authors have reported that they have no relationships relevant to the contents of this paper to disclose.
-
The 2025 American College of Cardiology/American Heart Association Acute Coronary Syndrome Guideline: A Personal Perspective J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Sunil V. RaoSection snippets Creating the Writing CommitteeGuideline writing committees comprise individuals of different but relevant expertise, representatives of collaborating professional societies, liaisons from the ACC/AHA Joint Committee on Clinical Practice Guidelines, and patients. For the 2025 ACS guideline, the expertise of the writing group spanned general cardiology, critical care cardiology, interventional
-
Shared Decision Making in the 2025 ACS Guideline J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Carolyn S.P. Lam, Erica S. SpatzSection snippets Why the Patient Perspective?Patients often experience acute coronary syndromes as life-altering events that rapidly unfold, leaving them overwhelmed and relieved to defer decision making to clinicians, especially during the acute phase, when fear and mental stress may be high.2,3 Yet even in this acute phase, there may be clinical equipoise, and shared decisions are paramount. For
-
Antiplatelet and Anticoagulant Therapy in the 2025 ACC/AHA Guideline for Acute Coronary Syndromes: Key Recommendations J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Behnood Bikdeli, Francisco Ujueta, Sina Rashedi, Azita H. Talasaz, Kushal T. Kadakia, Renato D. Lopes, Harvey D. White, Philippe Gabriel Steg, Gregory Piazza, Rasha K. Al-Lamee, David J. Cohen, Roxana Mehran, Harlan M. KrumholzSection snippets Funding Support and Author DisclosuresDr Bikdeli is supported by a Career Development Award from the American Heart Association and VIVA Physicians (#938814) outside of the submitted work; was supported by the Scott Schoen and Nancy Adams IGNITE Award; is supported by the Mary Ann Tynan Research Scientist award from the Mary Horrigan Connors Center for Women’s Health and Gender Biology
-
Perspective on the Choice and Duration of Dual Antiplatelet Therapy Recommendations in the 2025 Acute Coronary Syndrome Management Guideline J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Dennis T. Ko, Rasha K. Al-Lamee, Behnood Bikdeli, David J. Cohen, James L. Januzzi, Mitsuaki Sawano, Erica S. Spatz, Seng Chan YouSection snippets Class 1 Recommendations Regarding DAPT During Hospitalization 1.Prasugrel or ticagrelor is recommended in non–ST-segment elevation acute coronary syndromes (NSTE-ACS) and ST-segment elevation MI patients undergoing percutaneous coronary intervention (PCI). 2.Ticagrelor is recommended for NSTE-ACS patients managed without planned invasive evaluation.The benefit of DAPT in patients with
-
The 2025 Guideline Update Endorses Ticagrelor Monotherapy After ≥1 Month of DAPT Post-PCI in Patients With ACS: Is the Evidence Conclusive? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Sanjay Kaul, James M. BrophySection snippets Evidentiary Landscape and Quality of TrialsSupportive evidence for shortened DAPT followed by ticagrelor monotherapy is derived primarily from 5 trials3, 4, 5, 6, 7 that are summarized in Table 1. The heterogeneity between the trials is demonstrated in Table 1: •Trial design—2 placebo-controlled, double-blind trials4,7 and 3 open-label trial3,5,6; •Target populations—2 in patients
-
The 2025 ACS Guideline Update Endorses Ticagrelor Monotherapy ≥1 Month After DAPT Post-PCI: The Unbearable Lightness of Ticagrelor Monotherapy J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Roxana Mehran, Angelo Oliva, Marco ValgimigliSection snippets From Historical Dogma to Contemporary EvidenceFor nearly 2 decades, 12 months of DAPT has been the default strategy after ACS.2 This approach originated with the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial, which found that clopidogrel plus aspirin significantly reduced cardiovascular death, myocardial infarction (MI), or stroke compared with aspirin alone
-
Colchicine for Cardiovascular Disease: Navigating the Gap Between Evidence, Guidelines, and Clinical Practice J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Paul M RidkerSection snippets Funding Support and Author DisclosuresDr Ridker has received institutional research grant support from Kowa, Novartis, Amarin, Pfizer, Esperion, Novo Nordisk, and the National Heart, Lung, and Blood Institute; during the past 3 years has served as a consultant to Novartis, Agepha, Arrowhead, AstraZeneca, CSL Behring, CiVi Biopharma, Merck, SOCAR, Novo Nordisk, Eli Lilly, New Amsterdam
-
Reevaluating Beta-Blocker Recommendations Post-Myocardial Infarction: Perspective on the 2025 Guideline Update J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Sanjay KaulSection snippets Funding Support and Author DisclosuresDr Kaul is a consultant for Abbott, Amgen, Bayer, Edwards, Medtronic, ReCor, and Novo Nordisk.
-
ACS Management Guidelines: Tradition, Innovation, and the Gaps in Between J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Mohamad Alkhouli, David J. MoliternoSection snippets ACS Classification: An Unchanged Relic in Modern GuidelinesThe guideline writing committee has thoughtfully structured their recommendations around the management of ACS subtypes—unstable angina, NSTEMI, and STEMI—primarily attributed to atherosclerotic plaque erosion or rupture with subsequent thrombosis (type I myocardial infarction).2 However, a significant evidence gap persists
-
Mechanical Circulatory Support in Acute Myocardial Infarction–Cardiogenic Shock: 2025 Acute Coronary Syndrome Guideline in Context J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Karthik Murugiah, Theresa A. McDonagh, David J. Cohen, Sanket S. DhruvaSection snippets IABP: An Overdue DowngradeRoutine intra-aortic balloon pump (IABP) use in AMI-CS has been downgraded from Class 2; Level of Evidence: A in the 2013 STEMI guideline2 to Class 3 (no benefit). This change was based on the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock II) trial,3 which showed no mortality benefit at 30-day nor at 6-year follow-ups.4 Routine IABP use in AMI-CS
-
Maturation of Lipid Management in the 2025 ACC/AHA Acute Coronary Syndrome Guideline: What It Is and What It Might Have Been J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Julia Brandts, Kausik K. RaySection snippets Advancing LDL-C Targets and Combination TherapyThe new guidelines establish more stringent LDL-C targets, with therapy intensification considered reasonable if LDL-C falls between 55 and 69 mg/dL, in particular among patients with significant residual risk factors such as diabetes, polyvascular disease, elevated lipoprotein(a) [Lp(a)], or suspected familial hypercholesterolemia. This
-
The 2025 ACC/AHA Guideline for Acute Coronary Syndromes: A View From Down Under J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
John F. Beltrame, Stephen J. NichollsSection snippets Universal health careAustralia has a universal health care system, with 2 primary sources of funding and coordination. The federal government is the primary funder, responsible for delivery of primary and outpatient care, provision of medications, and diagnostic services. State governments are responsible for direct funding and management of their own public hospitals, where 69% of
-
The 2025 Guideline for the Management of Patients With Acute Coronary Syndromes: Asian Perspective J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Mitsuaki Sawano, Xin Du, Nathan D. Wong, Seng Chan You, Duk-Woo Park, Takashi Kubo, Toru Kondo, Ashok Seth, Khurram Nasir, Dennis T. Ko, Yuan Lu, Jian’an WangSection snippets East AsiaEast Asia faces rapidly aging populations and variable access to pharmaceutical agents and devices. Health systems are challenged by rising demand for complex care and the need to balance innovation with affordability. 1.Antithrombotic strategies for secondary prevention after acute coronary syndromes (ACS) vary across countries. In China, clopidogrel and ticagrelor are the
-
ACS Guidelines: Bridging the Transatlantic Divide J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
J.J. Coughlan, Rasha Al Lamee, Robert A. ByrneSection snippets Funding Support and Author DisclosuresDr Al Lamee has received an Intermediate Research Fellowship from the British Heart Foundation (FS/ICRF/22/26051); has served on the advisory boards of Janssen Pharmaceuticals, Abbott, Shockwave, and Philips; and has received speaker honoraria from Abbott, Philips, Medtronic, Servier, Omniprex, Shockwave, and Menarini. Dr Byrne has received research
-
American College of Cardiology/American Heart Association Acute Coronary Syndrome Guidelines: A Latin American Perspective J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-06-02
Remo H.M. Furtado, Carlos E. Rochitte, Jose Carlos Nicolau, Luis Eduardo Echeverría, Alexandra Arias-Mendoza, M. Cecilia Bahit, Francisco Padilla, Renato D. LopesSection snippets Cardiovascular Disease Burden in Latin AmericaThe Latin America and Caribbean region comprises almost one-tenth of the world’s population and 7% of the global gross domestic product.2 In the past, most deaths in Latin America were attributed to infectious diseases; however, Latin America now resembles more high-income countries with ischemic heart disease as the current leading cause
-
Adverse cardiac events associated with antibody drug conjugates in cancer patients: a retrospective analysis on the FAERS database and randomized controlled trials Cardiovasc. Res. (IF 10.2) Pub Date : 2025-06-02
Shaowei Zhuang, Bitao Wang, Enmin Wu, Jierong Lin, Wanxian Zeng, Maobai Liu, Jing Yang, Xiujuan ZhangAims Antibody Drug Conjugates(ADCs) are approved for use in cancers. Cardiovascular adverse reaction is a fatal adverse reactions associated with ADCs. The incidence of adverse cardiac events about ADCs have not been fully studied. We aimed to assess differences in cardiotoxicity among cancer patients treated with different ADCs. Methods and Results An observational retrospective pharmacovigilance
-
Lung ultrasound and mortality in a cardiogenic shock population: A prospective registry-based analysis Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-30
Guido Tavazzi, Costanza Natalia Julia Colombo, Matteo Pagnesi, Maurizio Bertaina, Andrea Montisci, Simone Frea, Marco Marini, Martina Briani, Lisa Patrini, Francesca Rossi, Letizia Bertoldi, Giulia Maj, Giovanna Viola, Carlotta Sorini Dini, Serafina Valente, Gaetano Maria De Ferrari, Nuccia Morici, Federico Pappalardo, Alice Sacco -
Targeting CD8+ T cells in cardiovascular diseases - current options and therapeutic perspectives Cardiovasc. Res. (IF 10.2) Pub Date : 2025-05-31
Rida Al-Rifai, Vincent Duval, Icia Santos-Zas, Théo Guyon, Luna Chetrit, Corinne Tanchot, Clement Cochain, Alma Zernecke, Marc Vocanson, Benoit Bensaid, Alain Tedgui, Heinz-Peter Schultheiss, Christian Baumeier, Christian Bailly, Hafid Ait-OufellaT lymphocytes expressing the CD8 coreceptor, often referred to as cytotoxic T-lymphocytes (CTL), are critical in defending against virus infections and cancers. CD8 encompasses a diverse family of proteins, including homodimers, heterodimers, isoforms, and splice variants. CD8αβ heterodimers are the predominant form of the CD8 membrane protein, often anchored to lipid rafts to facilitate the activation
-
Heart failure: assessment of the global economic burden Eur. Heart J. (IF 37.6) Pub Date : 2025-05-30
Mohammad Darvish, Abdul Shakoor, Lida Feyz, Jeroen Schaap, Nicolas M van Mieghem, Rudolf A de Boer, Jasper J Brugts, Robert M A van der BoonBackground and Aims Heart failure (HF) is a major public health issue, imposing substantial costs on healthcare systems and societies. This study aimed to provide a contemporary overview of its global economic impact. Methods A systematic search of four databases was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies reporting direct cost
-
Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trial Eur. Heart J. (IF 37.6) Pub Date : 2025-05-30
William A E Parker, Thomas A Nelson, Justin Lee, Heather M Judge, Ramzi A Ajjan, Johan Westerbergh, Agneta Siegbahn, Christina Christersson, John H Alexander, Renato D Lopes, Christopher B Granger, Elaine M Hylek, Lars Wallentin, Robert F StoreyBackground and Aims Oral anticoagulation reduces stroke risk in patients with atrial fibrillation (AF) but increases bleeding. Longer fibrin clot lysis time has been shown to predict adverse cardiovascular outcomes in acute coronary syndromes. This study explored relationships between fibrin clot lysis time at randomization and clinical outcomes in patients with AF enrolled in the Apixaban for Reduction
-
Data sharing statements: impact of journal policies across clinical research disciplines Eur. Heart J. (IF 37.6) Pub Date : 2025-05-30
Daniel Archer, Noah Barks, Mahad Chaudhry, Brody Dennis, Jacob Duncan, Annes Elfar, Taylor Gardner, Eli Paul, Micah Kee, Alicia Ito Ford, Matt VassarBackground and Aims Cardiovascular disease is a leading cause of mortality, with significant investments in research to improve treatment and prevention. Data sharing enhances transparency, reproducibility, and collaboration, yet data sharing statement (DSS) inclusion remains inconsistent. This study evaluates DSS prevalence, content, and influencing factors in high-impact cardiology journals, examines
-
Insights into the European heart failure epidemiology Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-30
Petar M. Seferović, Marija Polovina, Gianluigi Savarese, Ivan Milinković, Dejana Stanisavljević, Lars Lund, Ovidiu Chioncel, Magdy Abdelhamid, Yuri Lopatin, Stefan Störk, Manuel Anguita Sanchez, Massimo Piepoli, Aldo P. Maggioni, Ewa Jankowska, Antoni Bayes‐Genis, Alain Cohen Solal, Arsen Ristić, Mariya Tokmakova, Mehmet Birhan Yilmaz, Hadi Skouri, Davor Miličić, Offer Amir, Amina Rakisheva, GerasimosAimsThe Heart Failure Association (HFA) of the European Society of Cardiology (ESC), together with the National Heart Failure Societies (NHFS), designed the European Heart Failure (HF) Survey with an aim of assessing contemporary HF epidemiology, management resources, availability and reimbursement of guideline‐directed medications and devices, and structure of professional and patient organizations
-
Sweeteners: erythritol, xylitol and cardiovascular risk - friend or foe? Cardiovasc. Res. (IF 10.2) Pub Date : 2025-05-30
Bettina K Wölnerhanssen, Anne Christin Meyer-Gerspach, Arduino Arduini, Angelo D’Alessandro, Edoardo Gronda, Stefano Carugo, Mario Bonomini, Maurizio Gallieni, Valentina Masola, Anne Angelillo-Scherrer, Tommaso Prosdocimi, Gary D LopaschukHyperglycemia harms vascular health and promotes platelet aggregation. Reducing glucose concentration is crucial, and sugar alcohols may aid this effort. Used for over 50 years in food, cosmetic, and pharmaceutical industries, erythritol and xylitol minimally affect plasma glucose and insulin levels while promoting the release of beneficial gastrointestinal hormones such as e.g. glucagon-like peptide-1
-
Networking effectively with cardiovascular societies: strategies for meaningful engagement and career advancement Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2025-05-29
Purvi Parwani, F. Aaysha CaderEffective engagement with cardiovascular societies enhances professional development, academic growth and leadership opportunities. We describe practical strategies for cardiovascular professionals to connect with their peers, seek mentorship, advance professionally and contribute as active members of the cardiovascular society, to develop an impactful career and advance the field of cardiac medicine
-
Preventive stenting of vulnerable plaques in diabetic patients: is it worth it? Eur. Heart J. (IF 37.6) Pub Date : 2025-05-29
Diana A Gorog -
Rising demand vs limited access: should cardiologists perform mechanical thrombectomy? Eur. Heart J. (IF 37.6) Pub Date : 2025-05-29
Peter Lanzer -
Preventive percutaneous coronary intervention for non-flow-limiting vulnerable atherosclerotic coronary plaques in diabetes: the PREVENT trial Eur. Heart J. (IF 37.6) Pub Date : 2025-05-29
Min Chul Kim, Seung-Jung Park, Duk-Woo Park, Jung-Min Ahn, Do-Yoon Kang, Won-Jang Kim, Chang-Wook Nam, Jin-Ok Jeong, In-Ho Chae, Hiroki Shiomi, Hsien-Li Kao, Joo-Yong Hahn, Sung-Ho Her, Bong-Ki Lee, Tae Hoon Ahn, Kiyuk Chang, Jei Keon Chae, David Smyth, Gary S Mintz, Gregg W Stone, Youngkeun AhnBackground and Aims The efficacy and safety of preventive percutaneous coronary intervention (PCI) for treating vulnerable plaques in diabetic patients remain unclear. Methods The PREVENT (Preventive Coronary Intervention on Stenosis with Functionally Insignificant Vulnerable Plaque) trial was a randomized clinical trial that compared preventive PCI plus optimal medical therapy with optimal medical
-
Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial Eur. Heart J. (IF 37.6) Pub Date : 2025-05-29
K Lance Gould, Nils P Johnson, Amanda E Roby, Richard Kirkeeide, Mary Haynie, Tung Nguyen, Linh Bui, Monica B Patel, Danai Kitkungvan, Patricia Mendoza, Dejian Lai, Ruosha Li, Stefano Sdringola, David McPherson, Jagat NarulaBackground and Aims The randomized CENTURY trial tested the hypothesis that a comprehensive strategy integrating intense lifestyle modification and aggressive medical management to goals with revascularization reserved for severely reduced coronary flow capacity (CFC) by positron emission tomography (PET) would reduce risk factors, subsequent revascularization, death and myocardial infarction (MI)
-
Global heart failure epidemiology versus enrolment in pivotal trials: A formidable mismatch Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-29
Guillaume Baudry, Guowei Li, Ruoting Wang, Rebecca A.V. Newton, Luca Monzo, Nicolas Girerd, Ana Mocumbi, Faiez Zannad, Harriette G. C. Van SpallAimsRandomized clinical trials (RCTs) that inform international clinical practice guidelines should adequately represent regions burdened with disease. We aimed to assess the geographic representativeness of pivotal heart failure (HF) RCTs using two methodological approaches.Methods and resultsWe assessed the global geographic distribution of HF cases using the Global Burden of Disease 2021 dataset
-
Kidney injury in patients with heart failure‐related cardiogenic shock: Results from an international, multicentre cohort study Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-29
Jonas Sundermeyer, Caroline Kellner, Benedikt N. Beer, Lisa Besch, Angela Dettling, Letizia Fausta Bertoldi, Stefan Blankenberg, Jeroen Dauw, Dennis Eckner, Ingo Eitel, Tobias Graf, Patrick Horn, Joanna Jozwiak‐Nozdrzykowska, Paulus Kirchhof, Stefan Kluge, Axel Linke, Ulf Landmesser, Enzo Lüsebrink, Nicolas Majunke, Norman Mangner, Sven Möbius Winkler, Peter Nordbeck, Martin Orban, Federico Pappalardo -
Pharmacological Enhancement of Small Conductance Ca2+-Activated K+ Channels Suppresses Cardiac Arrhythmias in a Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia. Circ. Res. (IF 16.5) Pub Date : 2025-05-29
Roland Veress,Radmila Terentyeva,Andriy E Belevych,Fruzsina Perger,Zuzana Nichtova,Anastasia Pokrass,Yujia Cheng,Snizhana Chorna,Isabelle Deschenes,Sandor Gyorke,Bjorn Knollmann,Richard T Clements,Harpreet Singh,Bin Liu,Gyorgy Csordas,Shanna Hamilton,Dmitry TerentyevBACKGROUND Sarcolemmal small conductance Ca2+-activated K+ channels have the unique capacity to translate intracellular Ca2+ signal into repolarization, while mitochondrial SK channels can link Ca2+ cycling to mitochondrial function. We hypothesize that pharmacological enhancement of SK channels can be protective against malignant cardiac arrhythmias associated with disturbances in Ca2+ handling machinery
-
PRDM16, a new kid on the block in cardiovascular health and disease Cardiovasc. Res. (IF 10.2) Pub Date : 2025-05-29
Jore Van Wauwe, Hannelore Kemps, Pieter Vrancaert, Alexia Mahy, Robin Schellingen, Mandy O J Grootaert, Manu Beerens, Aernout LuttunTranscriptional regulation is essential for the development, homeostasis, and function of all organisms. Transcription factors and epigenetic modifiers play an indispensable role by direct or indirect interaction with DNA or chromatin. Although the role of transcription factor PRDM16 in adipose, hematopoietic, skeletal, and neural cell lineage specification is well-documented, its function within the
-
Reply to ‘Neuroendocrine regulatory effects of sex hormones on salt sensitivity of blood pressure’ Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2025-05-28
Sepiso K. Masenga, Annet KiraboWe appreciate the opportunity to reply to the points raised by M. Zhou et al. (Neuroendocrine regulatory effects of sex hormones on salt sensitivity of blood pressure. Nat. Rev. Cardiol. https://doi.org/10.1338/10.1038/s41569-025-01175-6 2025)1 on our Review (Masenga, S. K. et al. Salt sensitivity of blood pressure: mechanisms and sex-specific differences. Nat. Rev. Cardiol. https://doi.org/10.103
-
Neuroendocrine regulatory effects of sex hormones on salt sensitivity of blood pressure Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2025-05-28
Mi Zhou, Bing-hua Wang, Yu-chan Wang, Wen-jun Zhang, Li-xue YinWe read with great interest the Review by S. K. Masenga et al. (Salt sensitivity of blood pressure: mechanisms and sex-specific differences. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-025-01135-0 2025)1. The authors summarized the interactions between sex hormones, the renin–angiotensin–aldosterone system and the epithelial Na+ channel in the development of salt-sensitive hypertension1. Oestrogen
-
Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other cardiovascular disease Eur. J. Heart Fail. (IF 16.9) Pub Date : 2025-05-28
Biykem Bozkurt, Patrick Rossignol, Joseph A. Vassalotti -
Cardiac Ketone Body Oxidation Enhances Exercise Performance. Circ. Res. (IF 16.5) Pub Date : 2025-05-28
Kara R Gouwens,Ernesto Pena Calderin,Jada Okhiria,Daniel C Nguyen,Emily B Schulman-Geltzer,Yania Martinez-Ondaro,Maleesha De Silva,Helen E Collins,Yibing Nong,Sophia M Sears,Matthew A Nystoriak,Bradford G Hill -
Super-Enhancer-Driven HCG20 Promotes Pulmonary Hypertension Through U2AF2 Splicing. Circ. Res. (IF 16.5) Pub Date : 2025-05-28
Jian Mei,Wei Huang,Zitong Meng,Shiqing Wen,Langlin Ou,June Bai,Xiaoying Wang,Hao Yuan,Yanyu Li,Lixin Zhang,Yuwei You,Yingli Chen,Xiaodong Zheng,Fei Li,Song Wang,Xiangrui Zhu,Zhaosi Wang,Daling Zhu,Xiaowei Nie,Cui MaBACKGROUND Pulmonary artery endothelial cell (PAEC) dysfunction is a pathological hallmark of pulmonary hypertension (PH). Yet, the roles of long noncoding RNAs (lncRNAs) driven by super-enhancers (SEs) in PAECs are not well understood. In this study, we focused on the PAEC-specific SE-associated lncRNA HCG20 (HLA complex group 20) and to elucidate its role and underlying mechanisms in the progression
-
Association of Endothelial Dysfunction With Chronic Marijuana Smoking and THC-Edible Use JAMA Cardiol. (IF 14.8) Pub Date : 2025-05-28
Leila Mohammadi, Mina Navabzadeh, Nerea Jiménez-Téllez, Daniel D. Han, Emma Reagan, Jordan Naughton, Lylybell Y. Zhou, Rahul Almeida, Leslie M. Castaneda, Shadi A. Abdelaal, Kathryn S. Park, Keith Uyemura, Christian P. Cheung, Mehmet Nur Onder, Natasha Goyal, Poonam Rao, Judith Hellman, Jing Cheng, Joseph C. Wu, Gregory M. Marcus, Matthew L. SpringerImportanceRecreational and medicinal cannabis legalization has led to increased cannabis use. To understand the consequences for vascular health, we initiated the CANnabis: Does It Damage Endothelium (CANDIDE) study.ObjectiveTo investigate whether cannabis use is associated with vascular endothelial dysfunction.Design, Setting, and ParticipantsIn this cross-sectional study, sex- and age- matched healthy
-
GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction: Meta-Analysis of Randomized Clinical Trials JACC Heart Fail. (IF 10.3) Pub Date : 2025-05-28
João Sérgio Neves MD PhD, Catarina Vale MD, Ana Rita Leite MD, Adelino Leite-Moreira MD PhD, Faiez Zannad MD PhD, Javed Butler MD MPH MBA, Milton Packer MD, João Pedro Ferreira MD PhD -
Alcoholic Cardiomyopathy–Attributed Mortality in the United States, 2010 to 2020 JACC Heart Fail. (IF 10.3) Pub Date : 2025-05-28
Marco Zuin MD MS, Karola Jering MD, Bridget McGonagle BS, Alyssa Sato BA, Claudio Bilato MD PhD, Gregory Piazza MD MS -
Statins beat device-related in-stent neo-atherosclerosis: pathophysiology reigns supreme. Eur. Heart J. (IF 37.6) Pub Date : 2025-05-27
William Wijns,Shengxian Tu -
Weekly Journal Scan: Extending anticoagulation beyond 6 months after venous thromboembolism in patients with active cancer. Is low-dose apixaban the answer? Eur. Heart J. (IF 37.6) Pub Date : 2025-05-27
Mattia Galli,Carlo Patrono -
Letter by Luo et al Regarding Article, "Half-Life and Clearance of Cardiac Troponin I and Troponin T in Humans". Circulation (IF 35.5) Pub Date : 2025-05-27
Tianxiang Luo,Tiefu Zhao,Hanying Ma -
Electrical Alternance in a Patient With Type 1 Myotonic Dystrophy: What Diagnosis? Circulation (IF 35.5) Pub Date : 2025-05-27
Giovanni Vitale,Paolo Ortolani,Carmine Pizzi